<DOC>
	<DOCNO>NCT00996658</DOCNO>
	<brief_summary>The objective current study investigate efficacy , safety tolerability Linagliptin ( 5 mg daily ) compare placebo give 24 week add therapy metformin combination pioglitazone patient type 2 diabetes mellitus insufficient glycaemic control .</brief_summary>
	<brief_title>Linagliptin Versus Placebo Type 2 Diabetic Patients With Inadequate Glycaemic Control Metformin Combination With Pioglitazone</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Inclusion criterion : 1 . Diagnosis diabetes mellitus prior inform consent 2 . Patients treat metformin pioglitazone ( therapy unchanged 12 week ) 3 . Glycosylated haemoglobin A1 &gt; = 7.5 % &lt; = 10 % 4 . Age 18 less 80 5 . Body Mass index less equal 45 Exclusion criterion : 1 . Uncontrolled hyperglycaemia run period 2 . Myocardial infarction , stroke transient ischaemic accident within 3 month prior inform consent 3 . Impaired hepatic function 4 . Gastric pas surgery 5 . Treatment roziglitazone , GLP 1 analogue , DPP4 inhibitor insulin within 3 month prior inform consent 6 . Treatment antiobesity drug 7 . Current treatment systemic steroid time informed consent change dosage thyroid hormone within 6 week prior inform consent 8 . Premenopausal woman nurse pregnant childbearing potential practicing acceptable method birth control plan continue use method trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>